NCT00181766View on ClinicalTrials.gov

Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
ADHD NOS
Interventions
DRUG

Strattera (atomoxetine)

Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).

Trial Locations (1)

02138

Massachusetts General Hospital, Cambridge

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00181766 - Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) | Biotech Hunter | Biotech Hunter